CN1273152C - Capsule for treating diabetes and productive method thereof - Google Patents
Capsule for treating diabetes and productive method thereof Download PDFInfo
- Publication number
- CN1273152C CN1273152C CN 01112873 CN01112873A CN1273152C CN 1273152 C CN1273152 C CN 1273152C CN 01112873 CN01112873 CN 01112873 CN 01112873 A CN01112873 A CN 01112873A CN 1273152 C CN1273152 C CN 1273152C
- Authority
- CN
- China
- Prior art keywords
- powder
- separator
- capsule
- supercritical
- pressure
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000002775 capsule Substances 0.000 title claims abstract description 20
- 206010012601 diabetes mellitus Diseases 0.000 title claims abstract description 13
- 238000000034 method Methods 0.000 title claims description 3
- 239000000843 powder Substances 0.000 claims abstract description 50
- 241000208340 Araliaceae Species 0.000 claims abstract description 26
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 26
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 26
- 235000008434 ginseng Nutrition 0.000 claims abstract description 26
- 239000009636 Huang Qi Substances 0.000 claims description 25
- 239000000047 product Substances 0.000 claims description 22
- 239000000284 extract Substances 0.000 claims description 17
- HPCCGRCEBFBZQP-UHFFFAOYSA-N chromium;pyridine-3-carboxylic acid Chemical compound [Cr].OC(=O)C1=CC=CN=C1 HPCCGRCEBFBZQP-UHFFFAOYSA-N 0.000 claims description 16
- 238000000605 extraction Methods 0.000 claims description 16
- 239000011265 semifinished product Substances 0.000 claims description 14
- 239000007903 gelatin capsule Substances 0.000 claims description 12
- 238000004519 manufacturing process Methods 0.000 claims description 12
- 229940126678 chinese medicines Drugs 0.000 claims description 7
- 230000006837 decompression Effects 0.000 claims description 7
- 238000001035 drying Methods 0.000 claims description 7
- 239000000796 flavoring agent Substances 0.000 claims description 7
- 235000019634 flavors Nutrition 0.000 claims description 7
- 239000012530 fluid Substances 0.000 claims description 7
- 239000008176 lyophilized powder Substances 0.000 claims description 7
- 238000004064 recycling Methods 0.000 claims description 7
- 238000004806 packaging method and process Methods 0.000 claims description 6
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims description 4
- 229910002092 carbon dioxide Inorganic materials 0.000 claims description 2
- 239000001569 carbon dioxide Substances 0.000 claims description 2
- 238000000315 cryotherapy Methods 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 239000002994 raw material Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 16
- 239000003814 drug Substances 0.000 abstract description 8
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 abstract description 4
- 201000001421 hyperglycemia Diseases 0.000 abstract description 4
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 abstract description 3
- 229910052804 chromium Inorganic materials 0.000 abstract description 3
- 239000011651 chromium Substances 0.000 abstract description 3
- 210000003734 kidney Anatomy 0.000 abstract description 3
- 238000005728 strengthening Methods 0.000 abstract description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 abstract description 2
- 210000004185 liver Anatomy 0.000 abstract description 2
- 239000011707 mineral Substances 0.000 abstract description 2
- 235000001968 nicotinic acid Nutrition 0.000 abstract description 2
- 239000011664 nicotinic acid Substances 0.000 abstract description 2
- 229960003512 nicotinic acid Drugs 0.000 abstract description 2
- 239000000419 plant extract Substances 0.000 abstract description 2
- 210000000952 spleen Anatomy 0.000 abstract description 2
- 208000024891 symptom Diseases 0.000 abstract description 2
- 239000006187 pill Substances 0.000 abstract 2
- 229940107666 astragalus root Drugs 0.000 abstract 1
- 230000001717 pathogenic effect Effects 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 210000000496 pancreas Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 241000700605 Viruses Species 0.000 description 3
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 3
- 239000010839 body fluid Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- BJBUTJQYZDYRMJ-UHFFFAOYSA-N Kaempferol 3,7-dimethyl ether Chemical compound C=1C(OC)=CC(O)=C(C(C=2OC)=O)C=1OC=2C1=CC=C(O)C=C1 BJBUTJQYZDYRMJ-UHFFFAOYSA-N 0.000 description 2
- 229940127003 anti-diabetic drug Drugs 0.000 description 2
- 239000003472 antidiabetic agent Substances 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 239000002075 main ingredient Substances 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 description 1
- 206010018473 Glycosuria Diseases 0.000 description 1
- 206010061245 Internal injury Diseases 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 235000002791 Panax Nutrition 0.000 description 1
- 241000208343 Panax Species 0.000 description 1
- QFJUYMMIBFBOJY-UXZRXANASA-N Panaxatriol Chemical compound C[C@]1([C@H]2CC[C@@]3([C@@H]2[C@H](O)C[C@H]2[C@]3(C[C@@H](O)[C@H]3C(C)(C)[C@@H](O)CC[C@@]32C)C)C)CCCC(C)(C)O1 QFJUYMMIBFBOJY-UXZRXANASA-N 0.000 description 1
- VIXIMKLMEZTTTC-UHFFFAOYSA-N Panaxatriol Natural products CC1(C)CCCC(O1)C2CCC3(C)C2C(O)CC4C5(C)CCC(O)C(C)(C)C5C(O)CC34C VIXIMKLMEZTTTC-UHFFFAOYSA-N 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 229960002632 acarbose Drugs 0.000 description 1
- XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 229940089161 ginsenoside Drugs 0.000 description 1
- 229930182494 ginsenoside Natural products 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- -1 panoxadiol Natural products 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000000194 supercritical-fluid extraction Methods 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- GXPHKUHSUJUWKP-UHFFFAOYSA-N troglitazone Chemical compound C1CC=2C(C)=C(O)C(C)=C(C)C=2OC1(C)COC(C=C1)=CC=C1CC1SC(=O)NC1=O GXPHKUHSUJUWKP-UHFFFAOYSA-N 0.000 description 1
- 229960001641 troglitazone Drugs 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The present invention discloses a capsule for treating diabetes, which mainly comprises a capsule pill and powder filled in the capsule pill. The capsule is characterized in that the powder has the following components with the weight percentage: 6 to 7% of ginseng, 0.33 to 0.4% of trivalent nicotinic acid organic chromium and 93 to 94% of astragalus root. Because the capsule organically combines wild plant extracts with mineral substances, the capsule has the functions for treating hyperglycemia, nourishing the liver and kidney, relieving fatigue, strengthening the body, strengthening the heart, protecting the spleen, etc., is mainly used for treating I type and II type diabetic patients, and can treat external symptoms and pathogenic factors. Thereby, the capsule is a medicine with good treating effects.
Description
Technical field:
The invention belongs to field of medicaments and nourishing healthy field, specifically a kind of capsule and production method thereof for the treatment of diabetes.
Background technology:
China diabetes association adds up domestic diabetics to have reached 40,000,000 in November, 2000, and the patient is also constantly increasing every year, though antidiabetic drug is large in the variety in the market, but the Rezulin product that domestic and international diabetics is taken only play blood sugar lowering basically and keep the effect of symptom, cure far from, and the product that reaches therapeutic effect does not almost have.
Summary of the invention:
The object of the present invention is to provide a kind of capsule and production method thereof with treatment diabetes of better curative effect.
Technical scheme of the present invention is achieved in that a kind of capsule for the treatment of diabetes, it mainly comprises soft gelatin capsule and is contained in the interior powder of soft gelatin capsule, it is characterized in that: powder is made up of Radix Ginseng, Chromium nicotinate and the Radix Astragali, their weight percentages of components is, Radix Ginseng 6-7%, Chromium nicotinate 0.33-0.4%, Radix Astragali 93-94%, wherein, each component and be 100%.
The capsular production method of the above-mentioned glycosuria sugar of a kind of treatment is characterized in that:
A, Radix Ginseng and the Radix Astragali 2 flavor Chinese medicines are cleaned up section, section back natural drying, crushed after being dried becomes 60～70 order powder;
B, employing supercritical CO
2Fluid extraction technology extracts, and is specially: Radix Ginseng and 2 kinds of Chinese medicinal powder of the Radix Astragali and Chromium nicotinate are placed extractor, begin to supply with supercritical CO
2Extraction, condition is pressure 35-45Mpa, temperature 35-42 ℃, supercritical CO
2The extractor of from bottom to top flowing through, this moment, the medicated powder end was extracted, and extracting solution flows to first separator after the air relief valve decompression, contain fat prod and be insoluble to CO under the pressure about 7MPa
2And be deposited in bottom this separator; Extracting solution flows into second separator by first separator after reducing pressure, contain oil product and be insoluble to CO under the pressure about 2MPa
2, this moment, temperature was controlled at about 19～20 ℃, and required product is deposited in the bottom of this separator, CO
2Through the second separator recycling use, the semi-finished product that extract are the extractum shape;
C, the fast icy cabinet that the semi-finished product of extractum shape are taken out through negative 86 ℃ are frozen into lyophilized powder;
D, pulverize dry powder at least 100 purpose powder and sieve.
E, the powder that will sieve again are filled to through between the sterile working in No. 0 soft gelatin capsule, and every heavy 0.5g can adorn the box seal, packaging and warehousing.
The present invention is owing to organically be complexed to the wild plant extract with mineral, have treatment hyperglycemia, nourishing the liver and kidney, relieving fatigue, physical strength reinforcing, heart tonifying protects effects such as spleen, main treatment target is I, type ii diabetes patient, reaches and controls the effect that table effects a permanent cure, and be a kind of medicine with better curative effect, show through experimental result, this capsule is blood sugar lowering, glucose in urine significantly, removes pancreas virus, improves the function of islets of langerhans, stimulate the β cell to produce insulin, make it recover normal.This capsule can replenish the body fluid of human body, so the kidney tonifying effect is arranged.Though antidiabetic drug is large in the variety on the market now, but the product that reaches therapeutic effect does not almost have, the eutherapeutic product of therapeutical effect is badly in need of having in the domestic and international market now, because our new product Main Ingredients and Appearance is the complex of the wild plant Radix Astragali and Radix Ginseng and trivalent organic chromium.Our treatment principle is to remove pancreas virus, and stimulating pancreas and β cell reach and control the effect that table effects a permanent cure, and this capsule (also claiming " Chinese's recovering capsule ") through test of many times, has tentatively reached production capacity.With to put into practice curative effect good, this medicine all had unique curative effect to I, type ii diabetes to this capsule through the scientific research in 6 years.The method of medicinal supercritical extraction is extracted in its prescription, improved drug quality, few consumption just plays better curative effect, than also 3-5 days in advance common Chinese antihypelipidemic preparation onset time, this product compares with domestic and international similar drug, effect is remarkable, and following table 1 is for taking the inhibiting statistical table of different pharmaceutical to hyperglycemia.
Table 1
| Medicine | Example number n | Different time blood sugar increasing mean percentage X ± SE | The place of production | |
| 1 hour | 2 hours | |||
| Acarbose 0.5g | 120 | 132.9±19.7 | 141.0±22.4 | Germany |
| Chinese's health 0.5g | 120 | 52.5±11.7 | 68.8±18.8 | Our company |
| Chinese's health 1.0g | 120 | 31.6±12.9 | 26.8±19.9 | Our company |
Can find out that from table 1 Chinese's recovering capsule has the effect of remarkable inhibition hyperglycemia, experimental group is taken 1.0g, can significantly suppress blood sugar increasing, takes for a long time to have no side effect, cure rate reaches 30-35%, and the commercially available antihypelipidemic product of table 1 explanation Chinese's Kombi has more superiority.
Description of drawings:
Fig. 1 is a production method flow chart of the present invention
The specific embodiment:
Below the invention will be further described, and provide embodiment.The present invention is a kind of capsule for the treatment of diabetes, it mainly comprises soft gelatin capsule and is contained in the interior powder of soft gelatin capsule, it is different from prior art and is: powder is made up of Radix Ginseng, Chromium nicotinate and the Radix Astragali, their weight percentages of components is, Radix Ginseng 6-7%, Chromium nicotinate 0.33-0.4%, Radix Astragali 93-94%, wherein each component sum is 100%.This product Main Ingredients and Appearance is the complex of the wild plant Radix Astragali and Radix Ginseng and trivalent organic chromium, our treatment principle is to remove pancreas virus, stimulating pancreas and β cell, the Radix Ginseng effect in the medicine is thought: but strongly invigorating primordial QI, take off and promote the production of body fluid, calm the nerves, control frequent micturition, quench one's thirst, owe that void is multiple, the disease of all qi-blood-body fluid deficiencies admittedly; Effective component: ginsenoside, panoxadiol, panaxatriol, panax acid etc.; Trivalent nicotinic acid chromium: can improve the correction dysbolismus, improve glucose tolerance limit and insulin action; Effective component: chromic salt, nicotinic acid.
The Radix Astragali: cure mainly benefiting QI for strengthening the superficies, inducing diuresis to remove edema, poison holding, life, to control internal injury tired; Effective component: bitter principle, choline, kumatakenin, folic acid etc.
The capsular production method of a kind of treatment diabetes is characterized in that:
A, Radix Ginseng and the Radix Astragali 2 flavor Chinese medicines are cleaned up section, section back natural drying, crushed after being dried becomes 60～70 order powder;
B, employing supercritical CO
2Fluid extraction technology extracts, and is specially: Radix Ginseng and 2 kinds of Chinese medicinal powder of the Radix Astragali and Chromium nicotinate are placed extractor, begin to supply with supercritical CO
2Extraction, condition is pressure 35-45Mpa, temperature 35-42 ℃, supercritical CO
2The extractor of from bottom to top flowing through, this moment, the medicated powder end was extracted, and extracting solution flows to first separator after the air relief valve decompression, contain fat prod and be insoluble to CO under the pressure about 7MPa
2And be deposited in bottom this separator; Extracting solution flows into second separator by first separator after reducing pressure, contain oil product and be insoluble to CO under the pressure about 2MPa
2, this moment, temperature was controlled at about 19～20 ℃, and required product is deposited in the bottom of this separator, CO
2Through the second separator recycling use, the semi-finished product that extract are the extractum shape;
C, the fast icy cabinet that the semi-finished product of extractum shape are taken out through negative 86 ℃ are frozen into lyophilized powder;
D, pulverize dry powder at least 100 purpose powder and sieve.
E, the powder that will sieve again are filled to through between the sterile working in No. 0 soft gelatin capsule, and every heavy 0.5g can adorn the box seal, packaging and warehousing.
The purity of carbon dioxide is 95-98% when implementing, and required capital equipment is a supercritical CO
2Extraction equipment, disintegrating apparatus and cryotherapy equipment.
Embodiment 1
A, Radix Ginseng and the Radix Astragali 2 flavor Chinese medicines are cleaned up section, section back natural drying, crushed after being dried becomes 60 order powder;
B, employing supercritical CO
2Fluid extraction technology extracts, and is specially: Radix Ginseng and 2 kinds of Chinese medicinal powder of the Radix Astragali and Chromium nicotinate are placed extractor, and their percentage by weight is Radix Ginseng 6.1%, the Radix Astragali 93.5%, Chromium nicotinate 0.4%, begins to supply with supercritical CO
2Extraction, CO
2Purity be 95%, condition is pressure 35Mpa, 36 ℃ of temperature, supercritical CO
2The extractor of from bottom to top flowing through, this moment, the medicated powder end was extracted, and extracting solution flows to first separator after the air relief valve decompression, contain fat prod and be insoluble to CO under the pressure about 7MPa
2Be deposited in the separator bottom.Get extract and after reducing pressure, flow into second separator, contain oil product and under the pressure about 2MPa, be insoluble to CO by first separator
2, this moment, temperature was controlled at about 20 ℃, and required product is deposited in the bottom of separator, CO
2Through the second separator recycling use, the semi-finished product that extract are the extractum shape;
C, the fast icy cabinet that the semi-finished product of extractum shape are taken out through negative 86 ℃ are frozen into lyophilized powder;
D, dry powder pulverized be 100 purpose powder and sieve;
E, the powder that will sieve again are filled to through between the sterile working in No. 0 soft gelatin capsule, and every heavy 0.5g can adorn the box seal, packaging and warehousing.
Embodiment 2
Production method is pressed embodiment 1, only is that some physical parameters change, and is specially:
A, Radix Ginseng and the Radix Astragali 2 flavor Chinese medicines are cleaned up section, section back natural drying, crushed after being dried becomes 60 order powder;
B, employing supercritical CO
2Fluid extraction technology extracts, and is specially; Radix Ginseng and 2 kinds of Chinese medicinal powder of the Radix Astragali and Chromium nicotinate are placed extractor, and their percentage by weight is Radix Ginseng 6%, the Radix Astragali 93.67%, Chromium nicotinate 0.33%, begins to supply with supercritical CO
2Extraction, CO
2Purity be 96%, condition is pressure 45Mpa, 42 ℃ of temperature, supercritical CO
2The extractor of from bottom to top flowing through, this moment, the medicated powder end was extracted, and extracting solution flows to first separator after the air relief valve decompression, contain fat prod and be insoluble to CO under the pressure about 7MPa
2Be deposited in the separator bottom.Get extract and after reducing pressure, flow into second separator, contain oil product and under the pressure about 2MPa, be insoluble to CO by first separator
2, this moment, temperature was controlled at about 19 ℃, and required product is deposited in the bottom of separator, CO
2Through the second separator recycling use, the semi-finished product that extract are the extractum shape;
C, the fast icy cabinet that the semi-finished product of extractum shape are taken out through negative 86 ℃ are frozen into lyophilized powder;
D, dry powder pulverized be 120 purpose powder and sieve;
E, the powder that will sieve again are filled to through between the sterile working in No. 0 soft gelatin capsule, and every heavy 0.5g can adorn the box seal, packaging and warehousing.
Embodiment 3
A, Radix Ginseng and the Radix Astragali 2 flavor Chinese medicines are cleaned up section, section back natural drying, crushed after being dried becomes 60 order powder;
B, employing supercritical CO
2Fluid extraction technology extracts, and is specially; Radix Ginseng and 2 kinds of Chinese medicinal powder of the Radix Astragali and Chromium nicotinate are placed extractor, and their percentage by weight is Radix Ginseng 6.3%, the Radix Astragali 93.35%, Chromium nicotinate 0.35%, begins to supply with supercritical CO
2Extraction, CO
2Purity be 97%, condition is pressure 35Mpa, 36 ℃ of temperature, supercritical CO
2The extractor of from bottom to top flowing through, this moment, the medicated powder end was extracted, and extracting solution flows to first separator after the air relief valve decompression, contain fat prod and be insoluble to CO under the pressure about 7MPa
2Be deposited in the separator bottom.Get extract and after reducing pressure, flow into second separator, contain oil product and under the pressure about 2MPa, be insoluble to CO by first separator
2, this moment, temperature was controlled at about 20 ℃, and required product is deposited in the bottom of separator, CO
2Through the second separator recycling use, the semi-finished product that extract are the extractum shape;
C, the fast icy cabinet that the semi-finished product of extractum shape are taken out through negative 86 ℃ are frozen into lyophilized powder;
D, dry powder pulverized be 100 purpose powder and sieve;
E, the powder that will sieve again are filled to through between the sterile working in No. 0 soft gelatin capsule, and every heavy 0.5g can adorn the box seal, packaging and warehousing.
Claims (3)
1, a kind of capsule for the treatment of diabetes, it comprises soft gelatin capsule and is contained in the interior powder of soft gelatin capsule, it is characterized in that described powder made by following weight percentages Radix Ginseng 6.0-7%, Chromium nicotinate 0.33-0.4%, Radix Astragali 93-94%, wherein, described each raw material sum is 100%, and described powder gets by following method preparation:
A, Radix Ginseng and the Radix Astragali 2 flavor Chinese medicines are cleaned up section, section back natural drying, crushed after being dried becomes 60～70 order powder;
B, employing supercritical CO
2Fluid extraction technology extracts, and is specially: Radix Ginseng and 2 kinds of Chinese medicinal powder of the Radix Astragali and Chromium nicotinate are placed extractor, begin to supply with supercritical CO
2Extraction, condition is pressure 35-45Mpa, temperature 35-42 ℃, supercritical CO
2The extractor of from bottom to top flowing through, this moment, the medicated powder end was extracted, and extracting solution flows to first separator after the air relief valve decompression, contain fat prod and be insoluble to CO under the pressure about 7MPa
2And be deposited in bottom this separator; Extracting solution flows into second separator by first separator after reducing pressure, contain oil product and be insoluble to CO under the pressure about 2MPa
2, this moment, temperature was controlled at about 19～20 ℃, and required product is deposited in the bottom of this separator, CO
2Through the second separator recycling use, the semi-finished product that extract are the extractum shape;
C, the fast icy cabinet that the semi-finished product of extractum shape are taken out through negative 86 ℃ are frozen into lyophilized powder;
D, pulverize dry powder at least 100 purpose powder and sieve.
2, by the described a kind of capsular production method for the treatment of diabetes of claim 1, it is characterized in that:
A, Radix Ginseng and the Radix Astragali 2 flavor Chinese medicines are cleaned up section, section back natural drying, crushed after being dried becomes 60～70 order powder;
B, employing supercritical CO
2Fluid extraction technology extracts, and is specially: Radix Ginseng and 2 kinds of Chinese medicinal powder of the Radix Astragali and Chromium nicotinate are placed extractor, begin to supply with supercritical CO
2Extraction, condition is pressure 35-45Mpa, temperature 35-42 ℃, supercritical CO
2The extractor of from bottom to top flowing through, this moment, the medicated powder end was extracted, and extracting solution flows to first separator after the air relief valve decompression, contain fat prod and be insoluble to CO under the pressure about 7MPa
2And be deposited in bottom this separator; Extracting solution flows into second separator by first separator after reducing pressure, contain oil product and be insoluble to CO under the pressure about 2MPa
2, this moment, temperature was controlled at about 19～20 ℃, and required product is deposited in the bottom of this separator, CO
2Through the second separator recycling use, the semi-finished product that extract are the extractum shape;
C, the fast icy cabinet that the semi-finished product of extractum shape are taken out through negative 86 ℃ are frozen into lyophilized powder;
D, pulverize dry powder at least 100 purpose powder and sieve:
E, the powder that will sieve again are filled to through between the sterile working in No. 0 soft gelatin capsule, and every heavy 0.5g can adorn the box seal, packaging and warehousing.
3, by the described a kind of capsular production method for the treatment of diabetes of claim 2, it is characterized in that: the purity of carbon dioxide is 95-98%, and required capital equipment is a supercritical CO
2Extraction equipment, disintegrating apparatus and cryotherapy equipment.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 01112873 CN1273152C (en) | 2001-05-11 | 2001-05-11 | Capsule for treating diabetes and productive method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 01112873 CN1273152C (en) | 2001-05-11 | 2001-05-11 | Capsule for treating diabetes and productive method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1385172A CN1385172A (en) | 2002-12-18 |
| CN1273152C true CN1273152C (en) | 2006-09-06 |
Family
ID=4659619
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 01112873 Expired - Fee Related CN1273152C (en) | 2001-05-11 | 2001-05-11 | Capsule for treating diabetes and productive method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1273152C (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100438899C (en) * | 2007-01-11 | 2008-12-03 | 河北富格药业有限公司 | Medicine for treating diabetes and its preparing method |
| ES2395529B1 (en) | 2011-06-08 | 2014-04-11 | Pri, S.A. | SYNERGIC COMBINATION FOR THE TREATMENT OF MELLITUS DIABETES TYPE 2. |
-
2001
- 2001-05-11 CN CN 01112873 patent/CN1273152C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN1385172A (en) | 2002-12-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103750107B (en) | Health-care product with blood glucose reducing function | |
| CN103689152B (en) | Herbal tea for tonifying kidney and removing heat from liver and preparation method thereof | |
| CN101856405A (en) | Medicinal composition for treating type II diabetes mellitus and preparation method thereof | |
| CN1273152C (en) | Capsule for treating diabetes and productive method thereof | |
| CN112057501A (en) | Traditional Chinese medicine composition, traditional Chinese medicine ointment and external hot compress plaster for treating muscular atrophy and myasthenia | |
| CN1281225C (en) | Health-care food for diabetes mellitus patient | |
| CN108570116B (en) | Pleurotus citrinopileatus polysaccharide, preparation method and medical application in preventing and treating diabetes | |
| CN107019208A (en) | A kind of Chinese medicine ferment and preparation method thereof | |
| CN103055176B (en) | Traditional Chinese medicine for treating diabetes mellitus and preparation method thereof | |
| CN1589820A (en) | Chinese medicinal infusion for treating shingles, parotitis acute mamitis and its manufacturing method | |
| CN103705578A (en) | Traditional Chinese medicine preparation with functions of reducing blood fat and inhibiting blood glucose increase and preparation method thereof | |
| CN106729304B (en) | A kind of Chinese medicine for mitigating fasting or side reaction of dieting and preparation method thereof | |
| CN1483422A (en) | Medicine for treating diabetes | |
| CN105031248A (en) | Health care product which contains Se-enriched cordyceps and is capable of assisting in blood sugar level regulation | |
| CN1284548C (en) | Preparation technology of supplementing kind capsule | |
| CN110507707A (en) | A kind of Chinese medicine composition and preparation method thereof for treating type II diabetes | |
| CN1429594A (en) | Raw material in plant for regulating blood sugar extracted by using super critical CO2 extraction method and its preparation method | |
| CN104784472A (en) | Traditional Chinese medicine composition for decreasing blood sugar to treat diabetes | |
| CN1181876C (en) | Medicine for curing diabetes and its preparing method | |
| CN102380017A (en) | Medicament for treating diabetes and preparation method of medicament | |
| CN101822698A (en) | Method for preparing black fungus and pantotrichum hypoglycemic composition | |
| CN101721593A (en) | Medicinal and edible biological composition for improving diabetes and preparation method of capsule thereof | |
| CN112168861A (en) | Astragalus granules and preparation method thereof | |
| CN116508985A (en) | Auxiliary blood sugar reducing composition and health food | |
| CN1682980A (en) | Medicine for treating diabetes and its preparing method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: SHANGHAI ZHANWANG JINXIU TRADE CO., LTD. Free format text: FORMER OWNER: SHANGHAI ZHANWANG GROUP CO., LTD. Effective date: 20100505 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20100505 Address after: Jiading District Malu Town, Shanghai City No. 2968 Baoan road 201801 Patentee after: Shanghai prospect Jinxiu Trade Co., Ltd. Address before: Jiading District Malu Town, Shanghai City No. 2968 Baoan road 201801 Patentee before: Shanghai Zhanwang Group Co., Ltd. |
|
| C56 | Change in the name or address of the patentee |
Owner name: SHANGHAI ZHANWANG HEALTH MANAGEMENT CO., LTD. Free format text: FORMER NAME: SHANGHAI ZHANWANG JINXIU COMMERCE AND TRADE CO., LTD. |
|
| CP03 | Change of name, title or address |
Address after: 201801 room 1, building 2889, No. 103, Baoan Road, Shanghai, Jiading District Patentee after: Shanghai prospect Health Management Co., Ltd. Address before: Jiading District Malu Town, Shanghai City No. 2968 Baoan road 201801 Patentee before: Shanghai prospect Jinxiu Trade Co., Ltd. |
|
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20060906 Termination date: 20200511 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |